Pneumonia and influenza combined are the leading cause of infectious disease-related death in the United States [1] . The number of cases and incidence of influenza that require hospitalization fluctuate each year depending on circulating influenza viruses, level of immunity in the community, and influenza vaccine effectiveness. Many patients with influenza-associated hospitalizations present with a syndrome of lower respiratory tract infection (LRTI), including community-acquired pneumonia (CAP), acute exacerbation of chronic obstructive pulmonary disease (COPD), or acute bronchitis [2] . Influenza is one of the primary pathogens associated with CAP in hospitalized patients in the United States [3] .
In hospitalized patients with bacterial CAP, a delay in antibiotic therapy is associated with worse clinical outcomes [4] . To avoid delays in antibiotic administration, the standard of practice is the administration of empiric antibiotics as early as possible after suspected CAP diagnosis, preferably within hours of presentation to the hospital or emergency department [5] . Similarly, a delay in initiating antiviral therapy in hospitalized patients with influenza has been shown to be associated with worse clinical outcomes [6, 7] , hence current recommendations to initiate empiric treatment when influenza is suspected. However, in clinical practice, anti-influenza treatment for hospitalized patients with suspected influenza is not always initiated at admission and may be delayed while patients await results of diagnostic tests [8] .
Our objective in this study was to determine if the early initiation of empiric anti-influenza therapy for hospitalized patients with influenza-associated LRTIs (I-LRTI) during the influenza season resulted in improved clinical outcomes.
≥18 years) with symptoms consistent with acute LRTIs over 3 consecutive influenza seasons (2010-2011, 2011-2012, and 2012-2013) . Adult patients hospitalized at 1 of the 9 hospitals in Louisville, Kentucky, were eligible to participate if they did not have an order for oseltamivir or zanamivir from the admitting clinician written on their admission orders, had no known allergies to oseltamivir, and were able to give informed consent or had a proxy to give consent within 48 hours of hospitalization. Patients were excluded if they were pregnant or incarcerated. During 2010-2011, participants were enrolled from 4 hospitals; during 2011-2012, from 8 hospitals; and during 2012-2013, from all 9 hospitals admitting adult patients in Louisville.
Acute LRTI was defined as the presence of 2 respiratory signs or symptoms and 1 sign of acute infection at the time of admission. Respiratory signs and symptoms included new or increased cough, change in sputum production (color or quantity), evidence for reduced oxygenation (O 2 saturation <90% breathing on room air or, for patients on home oxygen therapy, a 1-L increase in their oxygen requirement), new onset shortness of breath, rapid respiratory rate (≥24 breaths per minute), or a record of new auscultatory findings (rales, rhonchi, wheezing). Signs or symptoms of acute infection included fever (temperature >38°C), hypothermia (temperature <35.6°C), subjective fever, or a report of chills or myalgias; changes in white blood cells (leukocytosis, leukopenia, abnormal differential [left shift, change in lymphocyte number or proportion]); or altered mental status. This was a composite definition of standard criteria used for diagnosis of acute bronchitis, acute exacerbation of chronic bronchitis, and CAP [5, 9, 10] .
All patients had a nasopharyngeal swab obtained at enrollment. Specimens were stored in M4 transport media and kept at −70°C for batched analysis. The swabs were used to detect 12 respiratory viruses, including influenza viruses, using the Luminex xTAG [11] , performed at the Division of Infectious Diseases Laboratory at the University of Louisville, Kentucky. Patients with I-LRTI were those tested with an influenza virus detected.
After informed consent was obtained, trained study personnel interviewed participants at enrollment and then daily while hospitalized. Trained study personnel abstracted information on underlying medical conditions and clinical outcomes from medical records onto a paper case report form. Personnel transferred the data into a secure, web-based data management system hosted by the University of Louisville, Division of Infectious Diseases.
The University of Louisville Human Subjects Research Protection Program Office (protocol 10.0465), the Robley Rex VA Medical Center Institutional Review Board (IRB; protocol 0068/00325), and each participating hospital prior to any enrollment (the Centers for Disease Control and Prevention [CDC] IRB granted reliance on local ethical review approvals) reviewed and approved the study.
Interventions
Patients were randomized 1:1 to standard of care (group A) or standard of care plus oral oseltamivir (group B) administered as early as possible but within 24 hours of enrollment. Oseltamivir was dosed at 75 mg twice daily for 7 days. Seven days was chosen to standardize treatment time across all levels of severity. The oseltamivir dose was adjusted in patients with renal insufficiency according to the package insert. Empiric antibiotic therapy was given according to standard clinical practice. Patients randomized to group A where a clinician later suspected or confirmed influenza virus infection could be started on oseltamivir at the discretion of the clinician caring for the patient.
Outcomes
The primary outcome was development of clinical failure during hospitalization in patients with laboratory-confirmed I-LRTI (per-protocol analysis). Clinical failure was a composite variable that included failure to reach clinical improvement within 7 days after hospitalization, transfer to an intensive care unit after 24 hours of hospitalization in a medical ward, or need for rehospitalization or death within 30 days; this is a modified definition from our previous work [12] . The following criteria for clinical improvement were collected daily during the first week after admission and defined according to 2001 American Thoracic Society-Infectious Diseases Society of America guidelines [13, 14] : improvement of signs and patient-reported symptoms of acute LRTI, afebrile for at least 8 hours when off antipyretics, >10% decrease or increase in white blood cell count from the prior day, and improved tolerance to oral feeding. A patient was considered "clinically improved" on the day that these 4 criteria were met.
Secondary outcomes included time to clinical improvement (described above), duration of hospitalization (day of discharge minus the day of admission), development of cardiovascular events during hospitalization, and long-term mortality at 1 year after hospitalization.
Randomization
A computer-generated randomizer was used to assign all patients into block sizes of 8. Patients randomized to group A were treated with standard of care according to the clinical management of the primary physician. Patients randomized to group B, the interventional arm, were given oseltamivir as early as possible along with the standard-of-care antibiotic therapy.
Study Populations
Patients randomized to 1 of the study groups were considered for the intent-to-treat (ITT) analysis. Patients in the per-protocol (PP) analysis included patients with laboratory-confirmed influenza; patients who did not withdraw from the study; in group A, patients who did not receive anti-influenza therapy after admission; and, in group B, patients who did not miss any doses of oseltamivir.
Sample Size
Previous studies have found a clinical failure rate of approximately 30% in hospitalized patients with CAP [12] . We estimated that I-LRTI patients randomized to group A would have a 30% clinical failure rate and that patients randomized to group B would have a clinical failure rate of 14%. Considering this effect size, we needed to analyze data from 200 patients with I-LRTI (100 in group A and 100 in group B) to allow for the detection of significant differences in the proposed outcome with 80% power with α = 0.05. Since I-LRTI was expected to occur in 20% of all hospitalized patients with CAP and other LRTIs, we needed to enroll 1000 patients with LRTI in order to achieve the goal of 200 patients hospitalized with laboratory-confirmed influenza LRTI.
Statistical Methods
Clinical failure was evaluated in both the ITT and PP samples using χ 2 tests. Secondary time-to-event outcomes (duration of hospital stay, time to clinical improvement) were evaluated using Kaplan-Meier curves, and the log-rank test was used to compare statistical differences between the 2 study groups. These outcomes were also presented as medians with interquartile ranges, and statistical differences were evaluated using the MannWhitney U test. Development of cardiovascular events and death after 1 year were evaluated using χ 2 tests. Secondary outcomes were evaluated in both the ITT and PP samples. Post hoc analyses were conducted for primary and secondary study outcomes for the PP sample. In these analyses, a subset of the data was used, one for patients with a duration of symptoms prior to admission <6 days and another for patients with a duration of symptoms prior to admission <3 days. P values < .05 were considered statistically significant in all analyses. R v3.4.1 (R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses.
RESULTS

Participant Flow
During the study period, 2407 patients were diagnosed with an LRTI and 1107 patients were enrolled; 556 into group A and 551 into group B. Figure 1 depicts the study flow chart for patients enrolled in each of the 2 study groups (ITT sample). From these groups, 55 patients randomized to group A and 41 patients randomized to group B had laboratory-confirmed influenza. From group A, 9 patients were started on antiviral therapy by the treating physician after randomization and 1 patient withdrew from the study, resulting in 45 patients included in the PP analysis. From group B, 8 patients missed antiviral doses during the 7-day treatment and 4 patients withdrew from the study, resulting in 29 patients included in the PP analysis.
Patient Characteristics: Intent to Treat
Patient characteristics and severity of disease at the time of hospitalization for each group are listed in Table 1 . There were no significant differences between study groups after adjusting for multiple comparisons. Prior to adjustment, there was a significant difference in arterial PaO 2 between the 2 groups (P = .023). The median time (interquartile range [IQR]) from hospital admission to oseltamivir administration for patients in group B was 22 hours (IQR, 9 hours). The median time from illness onset to enrollment was 5 days (IQR, 5 days) for both study groups. The median time from illness onset to oseltamivir administration was 6 days for group B (Table 1 and Supplementary Figure) .
Study Outcomes: Intent to Treat
Development of clinical failure in the ITT analysis for patients in group A occurred in 140 of the 556 patients (25%) and for patients in group B occurred in 129 of the 551 patients (24%; P = .561). All primary and secondary outcomes in the ITT sample are shown in Table 2 . Development of cardiovascular events after hospitalization occurred in 13 patients (2%) in group A and in 25 patients (5%) in group B (P = .065). Death 1 year after hospitalization was documented in 94 patients (23%) in group A and in 3 patients (22%) in group B (P = .727).
Study Outcomes: Per Protocol
Development of clinical failure in the PP sample for patients in group A occurred in 11 of 45 patients (24%) and for patients in group B occurred in 4 of 29 patients (14%) (P = .414). All primary and secondary outcomes in the PP sample are shown in Table 3 . Kaplan-Meier curves for time to clinical improvement and duration of hospital stay are depicted in Figures 2 and 3 . No significant differences were found in either sample for either outcome. Development of cardiovascular events during hospitalization occurred in no patients in group A and in 1 patient in group B. Death 1 year after hospitalization was documented in 6 patients in group A and in 2 patients in group B. No statistically significant differences were identified for any study outcomes.
Post Hoc Analyses
Primary and secondary outcomes for study patients included in the PP analysis within <6 days and <3 days from illness onset were evaluated. Post hoc analysis results are shown in Supplementary Tables 1 and 2 . No statistically significant differences were identified for any study outcomes.
DISCUSSION
In this study, we failed to demonstrate significant impact of empiric oseltamivir therapy at the time of hospital admission to reduce clinical failures among patients with I-LRTIs. While 
Severity of disease
Number of days with respiratory symptoms prior to admission, median (IQR)
5 (5) 5 (5) Intensive care unit admission, n (%) 71 (13) 64 (12) Altered mental status, n (%) 25 (4) 29 (5) Pneumonia severity index, median (IQR)
(50) 84 (45)
Syndrome, n (%)
Acute bronchitis 37 (7) 36 (7) Acute exacerbation of COPD 164 (29) 150 (27) Community-acquired pneumonia 355 (64) 362 (66)
Group A, randomized to standard of care; group B, randomized to empiric oseltamivir plus standard of care.
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
we sought to initiate antiviral therapy early in the course of the infection, the participants enrolled in our study were hospitalized after a median of 5 days from initial signs and symptoms, and the median time to oseltamivir initiation was 6 days after illness onset. Although antiviral therapy was given early in relation to hospital admission, therapy was not given early in regard to the natural history of influenza virus infection. Thus, our study results suggest that initiation of oseltamivir after more than 5 days of illness may not reduce clinical failure as defined among hospitalized patients with I-LRTIs. Previously published studies comparing clinical outcomes among hospitalized adults who received oseltamivir to outcomes among patients receiving no neuraminidase inhibitor treatment have been retrospective, observational studies and varied in quality [15] . While a few studies reported some effectiveness with treatment initiated 3, 4, and 5 days after illness onset [6, 16, 17] , others have indicated that oseltamivir treatment is less effective when initiated beyond 48 hours after illness onset in hospitalized patients [7, 18] .
Our study is the only published randomized study to attempt to evaluate the effect of oseltamivir in hospitalized adults.
As the study progressed over 3 seasons, an increasing number of clinicians ordered oseltamivir at admission due to updated recommendations and increased awareness [19] , decreasing the number of patients eligible for enrollment. We had additional data from an observational study that supported this hypothesis; concurrent with the trial, we enrolled a convenience sample of adults who had oseltamivir orders at the time of admission (and were not eligible for randomization). During study years 1 and 2, 3.7% and 1.6%, respectively, of all influenza-infected patients were represented in this group, while during year 3, they accounted for 20.1% of influenza cases (J. Ramirez, personal communication, January 2015). Thus, increasing oseltamivir use by clinicians likely decreased the population eligible for randomization, especially among those with influenza, and reduced the number of laboratory-confirmed influenza-associated cases enrolled in the randomized trial. A trial similar to ours, which attempted to randomize hospitalized adults to intravenous peramivir or no treatment, was terminated early due to the frequent use of oseltamivir by clinicians caring for enrolled patients during the study [20] . These 2 randomized, clinical trials highlight the difficulties in evaluating the effectiveness 
Secondary outcomes
Days to reach clinical improvement, median (IQR) 3 (2) 3 (2) .917
Length of hospital stay, median (IQR) 4 (4) 4 (3) .522
In-hospital mortality, n (%) 12 (2) 14 (3) .799
Mortality at 1 year, n (%) 94 (23) 84 (22) .727
Abbreviation: IQR, interquartile range. In-hospital mortality, n (%) 1 (2) 1 (3) >.999
Mortality at 1 year, n (%) 6 (19) 2 (10) .615
Abbreviation: IQR, interquartile range.
of influenza treatment in hospitalized adults using this design when the guidelines recommend empiric use of antivirals for hospitalized patients suspected or confirmed to have influenza virus infection. The primary limitation of our study is that we were not able to reach the number of patients with laboratory-confirmed I-LRTI that was originally expected based on our sample size calculation. Lack of adequate enrollment was due to mild influenza seasons in the study area (leading to lower incidence of influenza-associated hospitalizations during the study period) and early initiation of empiric antiviral therapy that became more frequently used among physicians in Louisville. The latter can be attributed to 2 factors: there was increased awareness of hospitalizations due to influenza LRTIs as part of physician education provided by the study investigators and enhanced communication with physicians regarding the importance of early antiviral therapy for patients suspected to have influenza. Also, the patients who enrolled in our study may not be representative of all hospitalized adults; we had a large proportion of patients with chronic pulmonary disease and with recent prior hospitalization. Our case definition for LRTI may have enhanced the proportion of patients with COPD and made it harder to identify differences in outcomes. It is possible that patients with COPD might wait longer to present to the hospital if they have medications to control symptoms at home.
In conclusion, in this prospective, randomized, clinical trial, we did not find a significant benefit of oseltamivir on the clinical outcomes of hospitalized patients with I-LRTIs, although we were likely underpowered due to the small number of patients with laboratory-confirmed influenza enrolled in the trial. Regardless of sample size limitations, most of our patients presented to the hospital after several days of signs and symptoms, likely minimizing any potential benefit expected from anti-influenza treatment. Strategies to encourage some patients to seek care earlier may offer a chance for earlier initiation of treatment, perhaps preventing hospitalization. An optimal treatment armamentarium for influenza illness that requires hospitalization should include agents with efficacy throughout the course of influenza illness.
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